Hebecell

Hebecell Corp. was founded in 2016 and primarily develops universal and cost-effective NK cell therapies based on its proprietary 3D pluripotent stem cell (PSC) platform. The ready-to-use NK cell product will be accessible to all patients globally for the treatment of cancer, viral infections, and autoimmune diseases. HebeCell's team includes several world-leading experts in stem cell biology, as well as experienced entrepreneurs and business developers.